Nonalcoholic Fatty Liver Disease : Focus on Lipoprotein and Lipid Deregulation

Abstract EN

Obesity with associated comorbidities is currently a worldwide epidemic and among the most challenging health conditions in the 21st century.

A major metabolic consequence of obesity is insulin resistance which underlies the pathogenesis of the metabolic syndrome.

Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of obesity and metabolic syndrome.

It comprises a disease spectrum ranging from simple steatosis (fatty liver), through nonalcoholic steatohepatitis (NASH) to fibrosis, and ultimately liver cirrhosis.

Abnormality in lipid and lipoprotein metabolism accompanied by chronic inflammation is the central pathway for the development of metabolic syndrome-related diseases, such as atherosclerosis, cardiovascular disease (CVD), and NAFLD.

This paper focuses on pathogenic aspect of lipid and lipoprotein metabolism in NAFLD and the relevant mouse models of this complex multifactorial disease.